JPS5872521A - Remedy for keloid - Google Patents

Abstract

PURPOSE:The titled remedy containing a human placental aqueous extract (human placental extract) as an active constituent. CONSTITUTION:A remedy for keloid, containing a human placental extract, preferably <=15,000, particularly 2,000-5,000, molecular weight, in an amount of 2-10%, preferably 4-6%, in the case of 25wt% aqueous solution of the extract, and formulated in the form of an ointment. The remedy is nontoxic with almost no side effect, e.g. pain, itching, rash or heat, etc. The human placental extract which is the active constituent is obtained by adding purified water to a placenta after the delivery which is washed with water, refrigerated and stored, grinding the placenta, centrifuging the ground placenta to give a supernatant liquid, adding purified water thereto, extracting the supernatant liquid at a high temperature and pressure, precipitating the extract, and adjusting the pH to remove proteins.

Description

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a keloid therapeutic agent containing an aqueous human placenta extract (hereinafter referred to as human placenta extract) as an active ingredient.

+Ploids are medically classified into idiopathic cephaloids and scarring keloids, but the therapeutic agent of the present invention is particularly effective for silver scar keloids (hereinafter referred to as keloids), which constitute the majority of keloids and frequently occur. Keloids occur as a result of burns, wounds, surgical procedures, etc., making the skin ugly and causing constant distress to patients and doctors, but to date there is no suitable treatment.
Its cure is almost impossible. Current treatments include therapeutic agents containing heparin-like substances as active ingredients, but the desired effects cannot be expected.

As a result of intensive research, the present inventors have discovered that when human placenta extract is used as an active ingredient, an epoch-making and excellent effect appears in Lloyd's Tomari. The bases, emulsifiers, preservatives, etc. used in the formulation are those normally used in ointments, but are not limited to (. (parts by weight, the same applies hereafter), in the case of an aqueous liquid, about 2 to 10 arcs, particularly 4 to 6 arcs, is suitable.

The human placenta extract used in the present invention is obtained by washing the postpartum placenta with water, adding purified water to the frozen preserved product, grinding and centrifuging to obtain a supernatant, and adding purified water to the supernatant. It is obtained by the conventional method of extracting the bacteria at high temperature and pressure, centrifuging, adjusting the pH, and removing bacteria.

When formulated into an ointment, etc., the higher the molecular weight, the more difficult it is to penetrate the skin. Goo~5. It is preferable to use fraxilon, mainly from Goo.

Human placenta extract contains polypeptides, amino acids, mucopolysaccharides, and nucleic acid components.

The therapeutic agent for keloids of the present invention is preferably used in the form of an ointment as described above, and in this case, the application is performed by observing the wound surface for 1 to 2 weeks after it has healed, and then thoroughly rubbing it on the surface and surrounding area of the keloid. . Depending on the case, gauze or the like may be applied to the entire surface and surrounding area of the keloid. It is preferable to apply it 1 to 3 times a day and apply it every day.

The therapeutic agent for keloids of the present invention is effective regardless of age, cause of injury, site, etc., and is also effective against keloids that have been treated for a considerable period of time after injury. For example, there are cases where it has been applied to keloids that have been around for 5 to 6 years and has shown remarkable results. Moreover, the keloid treatment agent of the present invention is non-toxic,
There are no side effects such as pain, itching, rash, or heat sensation when using it. When used on keloids after the wound has healed, the keloid becomes flat, the color returns to almost normal, and a very remarkable effect is produced.

The present invention will be explained by giving an example of manufacturing a human fetus extract, a prescription example of the keloid therapeutic agent of the present invention, and a clinical example.

(Example of production of human placenta extract) Placenta from normal delivery was washed with purified water and heated at -5 to -10°.
After freezing for 5 days at 100 mL, 1 sOO (b
Add az purified water, grind with a homogenizer, centrifuge once, add 1,000111 of purified water to the supernatant, and
Heat in a crepe at 120 aO for 50 minutes. After cooling, the mixture is centrifuged, the pH is adjusted to 4.0 with 50% acetic acid, and the mixture is further heated in an autoclave for 120 minutes. After cooling, it is centrifuged, medicated charcoal is added and filtered, the filter solution is adjusted to non-4.0 with 50% acetic acid, heated, and filtered to remove proteins.

Next, adjust the pH to 6.9 with 4M sodium hydroxide aqueous solution.
The extract was heated and concentrated, passed through a molecular sieve (Seven Fadex, a trade name of Pharmacia, etc.), and passed through a Milboa filter to obtain 250 ml of human placenta extract used in the present invention. This extract 1! l/ corresponds to 4 g of human placenta (yield: 25%) 0 The obtained human placenta extract has a molecular weight of approximately 10,000 to 1
6,000 fuchsia extract (hereinafter referred to as human placenta extract 1) and a molecular weight of 2.000 to 5. Goo's Fukushi Soun (hereinafter referred to as F Placenta Extract 2) was fractionated.

Next, a prescription example of an ointment using the separated human placenta extracts 1 and 2 will be shown, but the keloid therapeutic agent of the present invention is not limited to such a prescription example.

In addition, in the prescription examples, "Japanese medicine" and "cosmetic origin" refer to
These refer to the "Japanese Pharmacopoeia" and the "Standards for Cosmetic Ingredients," respectively.

Prescription example 1 (parts by weight) Human placenta extract 2 5.0
0 squalane (makeup primordium) 4
．． 67 White Vaseline (Japanese Bureau)
24.00 Stearyl alcohol (Japanese Bureau>
8.67 Myristic Acid Isobuc (Shohara &amp;
) 6. OQ stearic acid poliomyelitis 40 (Japanese Bureau) I
Chill phosphoric acid (cosmetic primordium) in J5 Mekishigong Yanru
2.27 Monostearin Strict Serine (8 stations)
2.00 Pyrene Glycol (11 groups) 6.67 Butyl Valanelle Benzoate (8 units > 0.10 Paraoxine Methyl Benzoate (8 units)
0.10 purified water (8 stations)
59.19 Total 100.00 Prescription example 2 (parts by weight) Human placenta extract 1 5.0
0 squalane (makeup primordium)
4.67 White Vaseline (8 stations)
24.00 Stearyl Alcohol C Japan Bureau>
8.67 Myristic acid isobutubisho (makeup primordium) 6. o.

Polyoxyl stearate 40 (8 stations)
1.331 lyoxyethylene cetyl ether phosphate (cosmetic primordium) 2.27 Glycerin monostearate (8 stations) 2. ．． 00 pyrene glycol (I[JI)
6.67 Butyl oxybenzoate (8 stations)
0.10 para methyl 4-2 benzoate (
8 stations) 0.10 purified water (8 stations)
s9.19 Total 100.00 Prescription example 6 (parts by weight) Human placenta extract 2 F)
, 00 white 9 serine (8 stations)
14.00 Isopvir myristate (cosmetic primordium)
4.50 stearyl alcohol/S' (E1
Bureau) 5.00 pyrene glycol (Ihara &) s, o.

Polyoxyl stearate 40 (8 stations)
2.00 lau stomach macrogol (8 games)
0.10 glyceryl monostearate (8 stations)
S, OO polyoxyethyl 9-oleyl ether (cosmetic primordium) 2.00 Methyl borosilicate xane (cosmetic primordium) 0
．． 20 Paraoquine methyl benzoate (8 stations)
0.10 Butyl paraoxybenzoate (8 stations)
0.10 sodium hydroxide (8 stations)
0.12 oxidation! Gnesium (8 stations)
0.40 purified water (8 stations)
58.48 Total 100.00 Clinical Example 1 The therapeutic agent for keloids of the present invention prepared in Prescription Example 1 (using human placenta extract with a molecular weight of 2.000 to s, ooo) was used to treat cases caused by various injury causes. A total of 106 patients were treated for this disease.

After observing the wound for 1 to 2 weeks after the wound had healed, it was applied to the keloid and its surrounding area. However, in the case of infants, gauze was applied and crimped onto the affected area.

The treatment results are categorized by age, gender, cause of injury, site of use, period of time until the start of use, amount of use, and period of use, and are shown in Tables 1 to 7.

What is particularly noteworthy is that none of the 106 cases had any side effects.

Tables 1 to 7 organize the data as follows. 8. The following criteria were used to judge the effectiveness by period of use: 6. Table 7: Period of use.

Remarkable effect = (height reduction) (range reduction) (coloration reduction) is 1
Effective if recognized within a month: (Reduction in height) (Reduction in range) (Reduction in coloring) is 6
Those found within the range are somewhat effective; those found within 6 months (reduction in height), (reduction in range), (decreased coloration) cannot be determined to be ineffective. Discontinued. Short period of use. Adverse side effects: Damage + Itching, 10 rashes, 10 fever sensations, prescription example 2
Patient 1 was treated for keloids in the same manner as in Clinical Example 1, except that the therapeutic agent for keloids of the present invention prepared with (molecular weight 10.000-15.000 (1) k) placenta extract was used.
This was done for 2 people.

The results are shown in Table 8.

The effectiveness was judged according to the following criteria. If the number has decreased by half within 3 months, if the height has become flattened within 6 months, if the coloring has disappeared, the height is valid! Slightly effective coloring for those that have been halved within 6 months: (Reduction in height) (Reduction in range) within 6 months
Comparing clinical examples 1 and 2 in which a decrease in coloration was observed, clinical example 1 using a human placenta extract with a small molecular weight (2,000 to s, ooo) was compared to a human placenta extract with a large molecular weight (10,000 s, ooo). 〜〜15.00
It can be seen that the healing effect was greater than that in Clinical Example 2 using 0).

Next, examples of the healing of keloids by the keloid therapeutic agent of the present invention are shown in FIGS. 1 to 6.

Figures 1, 3, and 5 are the states of keloids of three patients before use, and Figures 2, 4, and 6 are the states of keloids after treatment with the keloid treatment agent of the present invention, respectively. It is. Particularly, in FIGS. 3 and 4, the portions indicated by the dots are the portions in which the pycnoid therapeutic agent of the present invention was used, and a3) is the portion in which it was not used.

Situation Figure 1 Figure 3 Figure 5 Year 4
5 months old 3 years 2 months old 3 years old Gender Male Male
Parts used by women: Chest and abdomen Chest and abdomen Between use of thoraco and abdomen *si
Every day every day 8 usage period 2 power M2jlf
f 5 Rikigetsu 11 Henmakan 2 drawing, 4th v! From i and FIG. 6, it can be seen that the keloid has clearly degenerated.

When a conventionally used heparin-like substance was similarly applied, no change was observed even after 3 months.

[Brief explanation of the drawing]

Figures 1, pits, and 5 are the states of keloids of three patients before use, and Figures 2, 4, and 6 are the states of keloids after treatment with the keloid therapeutic agent of the present invention, respectively. be. (Drawing code) (4) 3 used parts φ) Non-heated parts Fig. 1 Fig. 2

Claims (1)

[Claims] 1. A keloid therapeutic agent containing an aqueous human placenta extract as an active ingredient. 2 Molecular weight of human placenta aqueous extract: approximately ts, oo. The therapeutic agent for keloid according to claim 1, which uses the following. 6 Molecular weight as human placenta aqueous extract: approximately 2,000-s
4. The therapeutic agent according to claim 1, 2 or 3, which is formulated into an ointment. Keloid therapeutic agent. 5) The keloid therapeutic agent according to claim 4, which contains 2 to 10 parts by weight of the placenta aqueous extract.